Vanda Pharmaceuticals Inc. (VNDA) Shares Bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp increased its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 1.7% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 199,578 shares of the biopharmaceutical company’s stock after purchasing an additional 3,305 shares during the period. Bank of New York Mellon Corp owned approximately 0.44% of Vanda Pharmaceuticals worth $3,573,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of VNDA. Stonepine Capital Management LLC boosted its position in shares of Vanda Pharmaceuticals by 1,482.2% during the 2nd quarter. Stonepine Capital Management LLC now owns 685,086 shares of the biopharmaceutical company’s stock worth $11,167,000 after purchasing an additional 641,786 shares during the period. Sei Investments Co. boosted its position in Vanda Pharmaceuticals by 15,516.7% in the 3rd quarter. Sei Investments Co. now owns 267,671 shares of the biopharmaceutical company’s stock valued at $4,792,000 after buying an additional 265,957 shares during the period. AJO LP boosted its position in Vanda Pharmaceuticals by 94.2% in the 2nd quarter. AJO LP now owns 541,927 shares of the biopharmaceutical company’s stock valued at $8,833,000 after buying an additional 262,833 shares during the period. Vanguard Group Inc. boosted its position in Vanda Pharmaceuticals by 7.5% in the 2nd quarter. Vanguard Group Inc. now owns 2,680,895 shares of the biopharmaceutical company’s stock valued at $43,698,000 after buying an additional 186,548 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Vanda Pharmaceuticals by 16.9% in the 2nd quarter. Renaissance Technologies LLC now owns 1,097,950 shares of the biopharmaceutical company’s stock valued at $17,897,000 after buying an additional 158,700 shares during the period. 88.43% of the stock is owned by hedge funds and other institutional investors.

In other news, SVP Gunther Birznieks sold 8,568 shares of Vanda Pharmaceuticals stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $15.26, for a total transaction of $130,747.68. Following the completion of the sale, the senior vice president now directly owns 118,366 shares of the company’s stock, valued at approximately $1,806,265.16. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Mihael Hristos Polymeropoulos sold 191,760 shares of Vanda Pharmaceuticals stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $15.30, for a total transaction of $2,933,928.00. Following the sale, the insider now directly owns 1,031,848 shares of the company’s stock, valued at $15,787,274.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 209,483 shares of company stock valued at $3,205,205. Corporate insiders own 7.60% of the company’s stock.

Shares of Vanda Pharmaceuticals Inc. (NASDAQ VNDA) opened at $15.55 on Friday. The stock has a market cap of $698.62, a price-to-earnings ratio of -48.59 and a beta of 1.29. Vanda Pharmaceuticals Inc. has a 1 year low of $11.90 and a 1 year high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.10). The business had revenue of $41.30 million during the quarter, compared to analysts’ expectations of $43.90 million. Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The company’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.01) EPS. analysts predict that Vanda Pharmaceuticals Inc. will post -0.44 EPS for the current year.

Several brokerages have commented on VNDA. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 19th. Oppenheimer set a $26.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, October 29th. BidaskClub raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. Piper Jaffray Companies raised their price target on shares of Vanda Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a research report on Thursday, September 14th. Finally, ValuEngine cut shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $21.50.

COPYRIGHT VIOLATION WARNING: This story was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3126376/vanda-pharmaceuticals-inc-vnda-shares-bought-by-bank-of-new-york-mellon-corp.html.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.